Clinical trial
Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human…
NCT00448253 · Emergent BioSolutions, Industry · Completed
Key facts
| NCT number | NCT00448253 |
|---|---|
| Title | Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum |
| Official title | Safety and Pharmacokinetics of Anthrax Immune Globulin Intravenous (Human), NP-015, in Healthy Volunteers. |
| Lead sponsor | Emergent BioSolutions, Industry |
| Collaborators | Department of Health and Human Services U.S. Fed |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Symptoms of Inhalational Anthrax |
| Intervention type | Biological |
| Interventions | NP-015 |
| Enrollment | 92 |
| Start date | Jul 1, 2007 |
| Primary completion | Aug 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Mar 16, 2007 |
| Last update posted | Mar 15, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: